Clinical research on dendritic cell vaccines to prevent postoperative recurrence and @entity3 of XXXX .

@entity1 @entity404 @entity96 @entity5 @entity405 @entity157 @entity3 @entity3646 @entity2841
UNASSIGNED: We aimed to evaluate dendritic cell (DC) @entity5 vaccines for preventing @entity96 recurrence and @entity3 . DCs were induced from mononuclear cells in the peripheral blood with recombinant @entity1 @entity2841 (rhGM-CSF) and recombinant @entity1 @entity3646 (rhIL-4), followed by sensitization with lysis of autologous @entity96 cells. One hundred and sixty @entity1 with @entity157 were randomly divided into two groups of 80. One group was treated postoperatively with six cycles of the DC @entity5 vaccine. The other group was treated postoperatively with six cycles of FOLFOX 6, beginning 1 week after surgery. After treatment with DC @entity5 vaccines, the levels of CD3+, @entity404 +, and @entity405 +, the ratio of @entity404 + to @entity405 + DC, and the serum levels of IL-12 and IFN-y were significantly increased both in comparison to the pre-treatment levels (P < 0.001) and to the chemotherapy group (P < 0.001). After a postoperative follow-up of 18 months, the metastatic recurrence rate in the DC @entity5 vaccine group was significantly lower than that in the chemotherapy group (17.50 vs 48.75%, P < 0.005), and the survival rate of the @entity1 in the DC @entity5 vaccine group was higher than that of the chemotherapy treatment group (86.25 vs 52.50%, P < 0.005). Treatment with DC @entity5 vaccines was safe and feasible. It can enhance the immunity of the @entity1 , reduce the rates of @entity3 and recurrence, and improve survival rates. This is a promising treatment for the prevention of postoperative recurrence in @entity1 with @entity96 .
